Amplia Therapeutics (ASX:ATX) Total Stockholders Equity: A$39.47 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ATX Amplia Therapeutics Ltd ASX:ATX
30 GF Score
Price A$0.13
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics Total Stockholders Equity?

Amplia Therapeutics ASX:ATX +4.00% 30 Total Stockholders Equity is A$39.47 Mil as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Amplia Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was A$39.47 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Amplia Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was A$0.08. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Amplia Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.01.

Amplia Therapeutics  (ASX:ATX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Amplia Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(39.472-0)/513.072
=0.08

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Amplia Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.089 + 0.252) / 39.472
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Total Stockholders Equity Related Terms

Amplia Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Total Stockholders Equity Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.85 15.84 11.42 21.03 39.47

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.42 12.77 21.03 42.93 39.47
ASX:ATX
30GF Score
Amplia Therapeutics Ltd ASX:ATX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of A$39.47 Mil mean?
Amplia Therapeutics (ASX:ATX) has a Total Stockholders Equity of A$39.47 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Amplia Therapeutics and its competitors.
Is Amplia Therapeutics' Total Stockholders Equity too high?
Amplia Therapeutics' current Total Stockholders Equity is A$39.47 Mil. Overall, Amplia Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Total Stockholders Equity compare to VRTX and REGN?
Amplia Therapeutics' Total Stockholders Equity of A$39.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Amplia Therapeutics and its competitors. Amplia Therapeutics's current Total Stockholders Equity is A$39.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Total Stockholders Equity of A$39.47 Mil. The current Total Stockholders Equity is A$39.47 Mil. Amplia Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Total Stockholders Equity is A$39.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
30GF Score

Get the complete analysis for ASX:ATX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13
Price